Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Revenues up 12% in the quarter driven by Keytruda

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
2Q Revenues: $11.8 billion (+12%)
2Q Earnings: $2.7 billion (+56%)
YTD Revenues: $22.6 billion (+10%)
YTD Earnings: $5.5 billion (earnings were $2.5 billion YTD18)
Comments: KEYTRUDA sales were up 58% in the quarter to $2.6 billion. Human Health Vaccines sales were up 33% to $2.0 billion. JANUVIA / JANUMET sales were down 6% to $1.4 billion.
GARDASIL / GARDASIL 9 sales were up 46% to $886 million. PROQUAD, M-M-R II and VARIVAX sales were up 58% to $675 million. BRIDION sales were up 16% to $278 million. ISENTRESS / ISENTRESS HD sales were down 19% to $247 million. ZETIA / VYTORIN sales were down 39% to $232 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters